Targeting DNA Damage Response

As research advances, we continue to expand our knowledge and understanding of novel targets in DNA damage response as potential therapeutic options in oncology. While PARP inhibitors have led the way, and are increasingly being recognized as a targeted therapeutic approach for patients with BRCA mutations and other indicators of susceptibility, agents targeting different DNA damage response pathways may potentially reshape the treatment landscape in oncology in the near future.

This curriculum explores the recent clinical advances with agents targeting different aspects of DNA damage response, their rationale for use, and emerging clinical data.